{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:38:20Z","timestamp":1790318300876,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jid.2020.05.110","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:07:06Z","timestamp":1593256026000},"page":"364-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3K\u03b1\/\u03b4 and HDAC"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-8011","authenticated-orcid":false,"given":"Chi-Heng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8747-7500","authenticated-orcid":false,"given":"Chen-Yen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5967-5190","authenticated-orcid":false,"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-632X","authenticated-orcid":false,"given":"Hua-Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-6315","authenticated-orcid":false,"given":"Taha","family":"Rakhshandehroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5257-0468","authenticated-orcid":false,"given":"Shervin","family":"Afghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-3675","authenticated-orcid":false,"given":"Laura","family":"Pincus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-9052","authenticated-orcid":false,"given":"Ronald","family":"Balassanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9062-2449","authenticated-orcid":false,"given":"James","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6229-7928","authenticated-orcid":false,"given":"Ryan","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3513-3885","authenticated-orcid":false,"given":"Sourav","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-7120","authenticated-orcid":false,"given":"Frank","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4411-4336","authenticated-orcid":false,"given":"Mark","family":"Moasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-6949","authenticated-orcid":false,"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.05.110_bib1","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.05.110_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.05.110_bib3","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.05.110_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2020.05.110_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200725","article-title":"The phosphoinositide-3 kinase (PI3K)-\u03b3,\u03b4 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies","volume":"13","author":"Faia","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2020.05.110_bib6","first-page":"1401","article-title":"Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas","volume":"89","author":"Gallardo","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jid.2020.05.110_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0609.2009.01239.x","article-title":"Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma","volume":"82","author":"Heider","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jid.2020.05.110_bib8","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b3,\u03b4 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jid.2020.05.110_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2020.05.110_bib10","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1600-0625.2010.01138.x","article-title":"A\u00a0novel xenograft model of cutaneous T-cell lymphoma","volume":"19","author":"Krejsgaard","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.05.110_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/labinvest.3780405","article-title":"p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides","volume":"82","author":"Navas","year":"2002","journal-title":"Lab Invest"},{"issue":"Suppl. 15","key":"10.1016\/j.jid.2020.05.110_bib12","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2018.36.15_suppl.7510","article-title":"Tenalisib, a dual PI3K \u03b4\/\u03b3 inhibitor: safety and efficacy results from an on-going phase I\/Ib study in relapsed\/refractory T-cell lymphoma","volume":"36","author":"Oki","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.05.110_bib13","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jid.2020.05.110_bib14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.0022-202x.2001.01682.x","article-title":"Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome","volume":"118","author":"Scarisbrick","year":"2002","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.05.110_bib15","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009","volume":"18","author":"Talpur","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.05.110_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1182\/bloodadvances.2019000844","article-title":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models","volume":"4","author":"Tarantelli","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jid.2020.05.110_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.0906-6705.2004.00201.x","article-title":"Establishment of a mouse xenograft model for mycosis fungoides","volume":"13","author":"Thaler","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.05.110_bib18","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and S\u00e9zary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.05.110_bib19","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jid.2020.05.110_bib20","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-07-1324","article-title":"Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive\/refractory mycosis fungoides and Sezary syndrome","volume":"13","author":"Yano","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2020.05.110_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/1087057114521867","article-title":"A\u00a0new Bliss independence model to analyze drug combination data","volume":"19","author":"Zhao","year":"2014","journal-title":"J\u00a0Biomol Screen"},{"key":"10.1016\/j.jid.2020.05.110_bib22","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20317243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20317243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:21:27Z","timestamp":1758302487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20317243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0022202X20317243"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.05.110","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.738233568.793576371","asserted-by":"object"}]},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3K\u03b1\/\u03b4 and HDAC","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.05.110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}